VEGFA and neoplasm: Schrand et al. [159,160] conjugated an agonistic 4-1BB aptamer to an aptamer that binds to VEGF that is widely expressed in tumor stroma; systemic administration of the conjugates in preclinical murine tumor models exhibited potent antitumor immunity against multiple unrelated tumors and an enhanced therapeutic index.